CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF
The present invention relates to series of peptidomimetic compounds selectively targeting CBX8 of polycomb chromobox protein homolog proteins. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases involved CBX8 pharmacology, including various cancers and leukemia, by administering therapeutically effective amounts of such compound alone or together with other therapeutics, are within the scope of this disclosure.
1 . A compound having the formula (I):
or a pharmaceutically acceptable salt thereof, wherein,
R 1 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, or one to two amino acid residues; each of which is optionally substituted;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 3 is an alkylamino, alkenylamino, cycloalkylamino, cycloalkenylamino, heteroalkylamino, or heteroalkenylamino; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl; and
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
2 . The compound according to claim 1 , wherein said compound has a formula (II):
wherein X represents four substituents, independently, hydrogen or halo;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 3 is an alkylamino, alkenylamino, cycloalkylamino, cycloalkenylamino, heteroalkylamino, or heteroalkenylamino; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl;
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and
R 6 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
3 . The compound according to claim 2 , wherein the compound has a formula (III):
wherein X represents a halo;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl;
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and
R 6 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
4 . The compound according to claim 3 , wherein R 4 is hydroxymethyl and X is chloro.
5 . The compound according to claim 3 , wherein the compound is
6 . The compound according to claim 5 , wherein the compound is used for the treatment of a prostate cancer.
7 . A pharmaceutical composition comprising the compound of claim 5 , together with one or more pharmaceutically acceptable diluents, excipients, or carriers.
8 . A pharmaceutical composition comprising one or more compounds of claim 3 , together with one or more pharmaceutically acceptable diluents, excipients, or carriers.
9 . A pharmaceutical composition comprising one or more compounds of claim 2 , together with one or more pharmaceutically acceptable diluents, excipients, or carriers.
10 . A pharmaceutical composition comprising one or more compounds of claim 1 , together with one or more pharmaceutically acceptable diluents, excipients, or carriers.
11 . A method for treating a patient with a disease caused by abnormal activities of CBX8 of polycomb chromobox protein homolog proteins comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the patient in need of relief from said disease.
12 . The method according claim 11 , wherein said disease is a prostate cancer.
13 . A method for treating a patient having a prostate cancer, comprising the step of administering a therapeutically effective amount one or more compounds having the formula (I):
or a pharmaceutically acceptable salt thereof, wherein,
R 1 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, or one to two amino acid residues; each of which is optionally substituted;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 3 is an alkylamino, alkenylamino, cycloalkylamino, cycloalkenylamino, heteroalkylamino, or heteroalkenylamino; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl; and
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
14 . A method for treating a patient having a prostate cancer according to claim 13 , wherein said prostate cancer is caused by an abnormal activities of CBX8.
15 . The method according to claim 13 , wherein said compound has a formula (II):
wherein X represents four substituents, independently, hydrogen or halo;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 3 is an alkylamino, alkenylamino, cycloalkylamino, cycloalkenylamino, heteroalkylamino, or heteroalkenylamino; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl;
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and
R 6 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
16 . A method for treating a patient having a prostate cancer according to claim 15 , wherein said prostate cancer is caused by an abnormal activities of CBX8.
17 . The method according to claim 14 , wherein the compound has a formula (III):
wherein X represents a halo;
R 2 is an alkyl, alkenyl, alkynyl, acyl, arylalkylacyl, arylacyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, arylalkyl, arylalkenyl, arylalkynyl, or heteroarylalkyl; each of which is optionally substituted;
R 4 is heteroalkyl, heteroalkenyl, heterocyclyl;
R 5 is hydrogen, an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted; and
R 6 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.
18 . A method for treating a patient having a prostate cancer according to claim 17 , wherein said prostate cancer is caused by an abnormal activities of CBX8.
19 . The method according to claim 17 , wherein said compound is
20 . A pharmaceutical composition for the treatment of a patient with a prostate cancer, comprising the compound of
or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable diluents, excipients, or carriers.